Comparative performance of the antibacterial activity of CuONPs synthesized with different conditions.

Use of reducing agents	Evaluation pattern against MDR bacteria	The source of bacteria investigated	Name of organisms	Doses of NPs (μg ml−1)		Zone of inhibition (mm)/growth of bacteria	References
				MIC	MBC
Gloriosa superba L. extract	Not done	Laboratory stock	1. Klebsiella aerogenes	100	—	12.00 ± 0.00	33
			2. Escherichia coli			7.33 ± 0.33
			3. Staphylococcus aureus			3.33 ± 0.33
			4. Pseudomonas desmolyticum			2.67 ± 0.33
Morinda tinctoria	Not done	Unknown	1. S. aureus	500	1000	10	61
			2. B. subtilis			16
			3. E. coli			12
			4. P. aeruginosa			10
Acanthospermum hispidum L. leaves extract	Not done	Human pathogen	1. E. coli	25	—	13	87
			2. P. aeruginosa	50		12
			3. S. pyogenus	100		17
			4. S. aureus	250		18
Gum karaya	Not done	Laboratory stock	1. E. coli	103 ± 4.7	125 ± 5.5	16.2 ± 0.8	88
			2. S. aureus	120 ± 8.1	135 ± 8.8	14.5 ± 0.6
Aerva javanica leaf extract	Not done	Laboratory stock	1. E. coli	128	128	6 ± 1	64
			2. P. aeruginosa			10 ± 1
			3. S. aureus			12 ± 1
			4. Acenetobacter			12 ± 1
Citrus limon	Not done	Laboratory stock	1. S. aureus	N/A	—	20	64
			2. E. coli			25
Bifurcaria bifurcate extract	Not done	Laboratory stock	1. Enterobacter aerogenes	20	—	14	55
			2. S. aureus			16
Justicia gendarussa			1. E. coli	75	—	16	58
			2. S. aureus			18
Citrus limon	Done	Laboratory stock	1. S. aureus	0.8	1.6	26 ± 0.5	This study
			2. E. coli	1.6	3.1	24 ± 0.1